Importance of Targeted and Novel Therapies in Respiratory Drugs Market to Remain High through 2022

Published Date : Sep 26, 2016

ALBANY, NY, Sep 26, 2016 - has added a new report, titled “Global Respiratory Drugs Market To 2022 - Pipeline And Market Characterized By Growing Prominence Of Targeted Therapies, With Asthma And Cystic Fibrosis Leading The Way,” to its offerings. This study presents an in-depth evaluation of the market and comprises key opportunities in the respiratory drugs market. Major drivers and impeders impacting the development of the market have also been presented through this study. The report also helps in understanding the commercial and current clinical landscape by considering factors such as diagnosis, treatment options, disease pathogenesis, and prognosis related to respiratory diseases.

According to the report, the respiratory disorders market is anticipated to rise from US$28.1 bn in 2015 to US$46.6 bn in 2022, expanding at a CAGR of 7.5% from 2016 to 2022. The study analyzes respiratory disorders pipeline and classifies it by molecule type, molecular target, and stage of development. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and with it, a single-product forecast. Despite the strong presence of the more traditional non-specific suggestive therapies in the respiratory disorder pipeline, there are promising targeted biologic therapies in the pipeline, which reflect their growing importance in this therapy area. Analysts estimate that around 908 products are currently active or in development for respiratory disorders.

Respiratory disorder treatments have developed significantly over the past few years, and with it the importance for targeted and novel therapies have also increased. The approval of products such as Orkambi in 2014 has given patients disease-modifying treatment options for cystic fibrosis. The introduction of the first biologic drug, omalizumab, which was approved in 2014 for the treatment of severe asthma was another groundbreaking discovery that has benefitted the respiratory drugs market. The trend of developing targeted therapies is on a rise and Nucala (mepolizumab) in November 2015 is one of the latest therapy. 

For Sample Copy, click here:

Small molecule therapies that aim to treat disease symptoms, rather than the actual cause, have conventionally been more prominent on the treatment landscape for respiratory disorders. Thus, treatment options are diverse in terms of their targets and mechanisms of action, which is most notable in cystic fibrosis. In cystic fibrosis, patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The treatment landscapes for asthma and chronic obstructive pulmonary disease (COPD) make use of similar symptomatic treatments such as bronchodilators and inhaled corticosteroids.

Analysts identify commercial opportunities in the respiratory disorder deals landscape by analyzing trends in licensing and co-development deals. The most significant deals that have occurred in this indication in recent years has also been given. In addition to this, the report profiles key companies such as GlaxoSmithKline, Vertex, AstraZeneca, Roche, Novartis, and Boehringer Ingelheim.

To order report Call Toll Free: 866-997-4948 or send an email on